OBJECTIVE: To describe the extent of adherence to the recommended neonatal zidovudine (ZDV) regimen administered to infants who have been exposed to the human immunodeficiency virus (HIV) to prevent mother-to-child transmission of HIV and to determine which maternal factors are associated with compliance. METHODS: HIV-infected women (n = 87) who were participating in a larger study of perinatal transmission at 3 inner-city New York City hospitals were interviewed 2 to 6 weeks' postpartum to assess adherence to neonatal prophylaxis, social support, social network factors, and depression. In addition, plasma samples of 45 of their infants were assayed for ZDV levels. RESULTS: A majority of women (71%) administered all of the prescribed 4 daily doses in the previous week, as measured by interview; self-reported adherence was not associated with any maternal characteristics. In contrast, poor adherence, as measured by lower infant ZDV plasma levels, was associated with asymptomatic HIV illness in the mother and having 2 or more other children; good adherence, as indicated by higher ZDV levels, was associated with the presence of a maternal social support network, disclosure of HIV infection, and mothers' adherence to their own ZDV regimens during pregnancy. In multivariate regression analyses, maternal asymptomatic status (beta = -0.40) was associated with lower infant ZDV levels, and maternal adherence during pregnancy (beta = 0.37) was associated with higher levels. CONCLUSIONS: Women who are HIV asymptomatic and lack a social support network are more likely not to comply with the recommended neonatal prophylactic regimen of antiretroviral therapy. Future studies should address the prenatal period and social network factors, such as disclosure of serostatus, and the custody of other children.
OBJECTIVE: To describe the extent of adherence to the recommended neonatal zidovudine (ZDV) regimen administered to infants who have been exposed to the human immunodeficiency virus (HIV) to prevent mother-to-child transmission of HIV and to determine which maternal factors are associated with compliance. METHODS:HIV-infectedwomen (n = 87) who were participating in a larger study of perinatal transmission at 3 inner-city New York City hospitals were interviewed 2 to 6 weeks' postpartum to assess adherence to neonatal prophylaxis, social support, social network factors, and depression. In addition, plasma samples of 45 of their infants were assayed for ZDV levels. RESULTS: A majority of women (71%) administered all of the prescribed 4 daily doses in the previous week, as measured by interview; self-reported adherence was not associated with any maternal characteristics. In contrast, poor adherence, as measured by lower infantZDV plasma levels, was associated with asymptomatic HIV illness in the mother and having 2 or more other children; good adherence, as indicated by higher ZDV levels, was associated with the presence of a maternal social support network, disclosure of HIV infection, and mothers' adherence to their own ZDV regimens during pregnancy. In multivariate regression analyses, maternal asymptomatic status (beta = -0.40) was associated with lower infantZDV levels, and maternal adherence during pregnancy (beta = 0.37) was associated with higher levels. CONCLUSIONS:Women who are HIV asymptomatic and lack a social support network are more likely not to comply with the recommended neonatal prophylactic regimen of antiretroviral therapy. Future studies should address the prenatal period and social network factors, such as disclosure of serostatus, and the custody of other children.
Authors: M L Lindegren; R H Byers; P Thomas; S F Davis; B Caldwell; M Rogers; M Gwinn; J W Ward; P L Fleming Journal: JAMA Date: 1999-08-11 Impact factor: 56.272
Authors: J B Lackner; J G Joseph; D G Ostrow; R C Kessler; S Eshleman; C B Wortman; K O'Brien; J P Phair; J Chmiel Journal: J Nerv Ment Dis Date: 1993-01 Impact factor: 2.254
Authors: D Moodley; K Pillay; K Naidoo; J Moodley; M A Johnson; K H Moore; P N Mudd; G E Pakes Journal: J Clin Pharmacol Date: 2001-07 Impact factor: 3.126
Authors: E R Cooper; R P Nugent; C Diaz; J Pitt; C Hanson; L A Kalish; H Mendez; C Zorrilla; R Hershow; J Moye; V Smeriglio; M G Fowler Journal: J Infect Dis Date: 1996-12 Impact factor: 5.226
Authors: F D Boucher; J F Modlin; S Weller; A Ruff; M Mirochnick; S Pelton; C Wilfert; R McKinney; M J Crain; M M Elkins Journal: J Pediatr Date: 1993-01 Impact factor: 4.406
Authors: N A Wade; G S Birkhead; B L Warren; T T Charbonneau; P T French; L Wang; J B Baum; J M Tesoriero; R Savicki Journal: N Engl J Med Date: 1998-11-12 Impact factor: 91.245
Authors: Penelope A Demas; Donald M Thea; Jeremy Weedon; Janis McWayne; Mahrukh Bamji; Genevieve Lambert; Ellie E Schoenbaum Journal: Women Health Date: 2005
Authors: Kendra Hatfield-Timajchy; Jennifer L Brown; Lisa B Haddad; Rana Chakraborty; Athena P Kourtis Journal: AIDS Patient Care STDS Date: 2016-07 Impact factor: 5.078
Authors: Karina M Berg; Penelope A Demas; Andrea A Howard; Ellie E Schoenbaum; Marc N Gourevitch; Julia H Arnsten Journal: J Gen Intern Med Date: 2004-11 Impact factor: 5.128
Authors: Daniel J Merenstein; Michael F Schneider; Christopher Cox; Rebecca Schwartz; Kathleen Weber; Esther Robison; Monica Gandhi; Jean Richardson; Michael W Plankey Journal: Pediatrics Date: 2008-04 Impact factor: 7.124
Authors: Maria C Raven; John C Billings; Lewis R Goldfrank; Eric D Manheimer; Marc N Gourevitch Journal: J Urban Health Date: 2008-12-12 Impact factor: 3.671
Authors: Cristina B Hofer; D Robert Harris; Mariza C Saavedra; Jessica E Haberer; Juliana Romeiro; Marisa M Mussi-Pinhata; Erica Stankievich; Ivete M Gomes; Regis Kreitchmann; Jennifer S Read Journal: Braz J Infect Dis Date: 2013-05-13 Impact factor: 3.257